We gratefully acknowledge support from
the Simons Foundation and member institutions.
Full-text links:


Current browse context:


Change to browse by:

References & Citations


(what is this?)
CiteULike logo BibSonomy logo Mendeley logo del.icio.us logo Digg logo Reddit logo ScienceWISE logo

Quantitative Biology > Molecular Networks

Title: DCcov: Repositioning of Drugs and Drug Combinations for SARS-CoV-2 Infected Lung through Constraint-Based Modelling

Abstract: The 2019 coronavirus disease (COVID-19) became a worldwide pandemic with currently no effective antiviral drug except treatments for symptomatic therapy. Flux balance analysis is an efficient method to analyze metabolic networks. It allows optimizing for a metabolic function and thus e.g., predicting the growth rate of a specific cell or the production rate of a metabolite of interest. Here flux balance analysis was applied on human lung cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to reposition metabolic drugs and drug combinations against the replication of the SARS-CoV-2 virus within the host tissue. Making use of expression data sets of infected lung tissue, genome-scale COVID-19-specific metabolic models were reconstructed. Then host-specific essential genes and gene-pairs were determined through in-silico knockouts that permit reducing the viral biomass production without affecting the host biomass. Key pathways that are associated with COVID-19 severity in lung tissue are related to oxidative stress, as well as ferroptosis, sphingolipid metabolism, cysteine metabolism, and fat digestion. By in-silico screening of FDA approved drugs on the putative disease-specific essential genes and gene-pairs, 45 drugs and 99 drug combinations were predicted as promising candidates for COVID-19 focused drug repositioning (this https URL). Among the 45 drug candidates, six antiviral drugs were found and seven drugs that are being tested in clinical trials against COVID-19. Other drugs like gemcitabine, rosuvastatin and acetylcysteine, and drug combinations like azathioprine-pemetrexed might offer new chances for treating COVID-19.
Subjects: Molecular Networks (q-bio.MN); Genomics (q-bio.GN)
Cite as: arXiv:2103.13844 [q-bio.MN]
  (or arXiv:2103.13844v1 [q-bio.MN] for this version)

Submission history

From: Ali Kishk [view email]
[v1] Thu, 25 Mar 2021 13:51:37 GMT (4548kb)

Link back to: arXiv, form interface, contact.